Oncology
Identifying & reducing barriers to oncology clinical research at site level
Early Phase Oncology
ICON’s clinical and operational expertise are founded on successful principles, with on-demand access to critical and supportive resources tailored to a early phase oncology trials.
Recent developments in cancer immunotherapy illustrate virtually unprecedented clinical benefit in some advanced cancer patients, and the potential for cure seems tangible. In line with transforming patient care, we have also already begun to transform drug development.
ICON conducts clinical studies in both solid and haematological tumours including breast, lung, gastric, HCC, prostate, multiple myeloma, AML, lymphoma and leukaemia.
ICON services your oncology trial can benefit from include:
- Medical ImagingMedical imaging enables improved decision making, increased efficiency, and can reduce trial costs.
- Site and Patient RecruitmentICON's proven paradigm bridges the gap between patients and clinical research sites.
- Real World IntelligenceResources and expertise to identify, generate, synthesize and communicate evidence of treatment value and safety
- FIRECRESTFIRECREST digital solutions increase efficiency in clinical trials by driving site performance.
- Laboratory ServicesICON provides a full range of laboratory services that are dedicated exclusively to clinical development.
- Value Access and OutcomesOur consultants can advise you on developing market access and pricing strategies.
Medical Imaging
Medical imaging enables improved decision making, increased efficiency, and can reduce trial costs.
Site and Patient Recruitment
ICON's proven paradigm bridges the gap between patients and clinical research sites.
Real World Intelligence
Resources and expertise to identify, generate, synthesize and communicate evidence of treatment value and safety
FIRECREST
FIRECREST digital solutions increase efficiency in clinical trials by driving site performance.
Laboratory Services
ICON provides a full range of laboratory services that are dedicated exclusively to clinical development.
Value Access and Outcomes
Our consultants can advise you on developing market access and pricing strategies.
Transforming patient outcomes
The explosion of information about the genetic aberrations underlying cancer has led to several changes in the paradigm of how we develop drugs for this disease. We believe that transformation of the outcomes for patients with cancer will require detailed understanding of these genetic aberrations in each patient’s cancer at diagnosis.
Targeted therapies, novel immunotherapies and the ability to combine these agents together successfully will be important in the development of effective and tolerable treatment regimens.
Oncology blogs
CAR-T therapies
Scaling Up CAR-T Therapies Requires Overcoming Manufacturing, Regulatory and Distribution Challenges.
Patient centricity in Oncology trials
Patient centric strategies to focus more on patient needs and increase efficiencies.
Restricted Mean Survival Time (RMST) in Oncology trials
Biostatistics: Using Restricted Mean Survival Time (RMST) in Oncology Trials to Improve Outcomes.
Smart bioanalytical strategies in Immuno-Oncology trials
Biomarker-based methods and how they can be leveraged to add value to oncology trials.
Immuno-Oncology: Am I choosing the right Biomarker?
ICON has been immersed in the development of both passive and active immunotherapy approaches, allowing sponsors to overcome challenges in Immuno-Oncology.
Overcoming limitations in Multiple Myeloma trial designs
The discovery of novel biomarkers has made MMMultiple Myeloma diagnosis and monitoring much easier and more efficient.
Novel cancer trials demand that participating sites act differently
The evolution of adoptive cellular transfer (ACT) for the treatment of lymphoma, leukaemia and myeloma patients has grown exponentially.
Oncology clinical trials in Asia Pacific
Although Asia Pacific (APAC) is sometimes referred to as a homogenous unit, it is a heterogeneous region, with divergent countries, languages, populations and cultures.
Innovation in Oncology drug development
Significant progress has been made in our understanding of the molecular lesions responsible for tumor cells.
Immunotherapy in cancer treatment
Immunotherapy has been the focus of medical research for many years, and scientists continue to experiment with and learn about this form of therapy in cancer treatment.